Zivo Bioscience, Inc.
ZIVO
$17.80
-$0.10-0.56%
| Weiss Ratings | ZIVO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | ZIVO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ZIVO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.64 | |||
| Price History | ZIVO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -1.11% | |||
| 30-Day Total Return | -10.10% | |||
| 60-Day Total Return | -11.00% | |||
| 90-Day Total Return | -8.72% | |||
| Year to Date Total Return | -17.09% | |||
| 1-Year Total Return | 100.22% | |||
| 2-Year Total Return | -3.05% | |||
| 3-Year Total Return | -16.90% | |||
| 5-Year Total Return | -57.86% | |||
| 52-Week High % Change | -19.19% | |||
| 52-Week Low % Change | 471.88% | |||
| Price | ZIVO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $22.15 | |||
| 52-Week Low Price | $3.13 | |||
| 52-Week Low Price (Date) | May 31, 2024 | |||
| 52-Week High Price (Date) | Nov 11, 2024 | |||
| Valuation | ZIVO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 68.31M | |||
| Enterprise Value | 68.53M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -4.90 | |||
| Earnings Per Share Growth | -7.68% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 774.89 | |||
| Price/Book (Q) | -29.99 | |||
| Enterprise Value/Revenue (TTM) | 867.47 | |||
| Price | $17.80 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -5.02 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | ZIVO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 3.41M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ZIVO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 248 452 9866 | |||
| Address | 21 East Long Lake Road Bloomfield Hills, MI 48304 | |||
| Website | www.zivobioscience.com | |||
| Country | United States | |||
| Year Founded | -- | |||
| Profitability | ZIVO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -17,293.67% | |||
| Profit Margin | -17,331.64% | |||
| Management Effectiveness | ZIVO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -657.43% | |||
| Return on Equity | -- | |||
| Income Statement | ZIVO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 79.00K | |||
| Total Revenue (TTM) | 79.00K | |||
| Revenue Per Share | $0.02 | |||
| Gross Profit (TTM) | 26.10K | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | -13.66M | |||
| Net Income (TTM) | -13.69M | |||
| Net Income Avl. to Common (TTM) | -13.69M | |||
| Total Revenue Growth (Q YOY) | 166.95% | |||
| Earnings Growth (Q YOY) | -24.31% | |||
| EPS Diluted (TTM) | -4.90 | |||
| EPS Diluted Growth (Q YOY) | 36.73% | |||
| Balance Sheet | ZIVO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 159.40K | |||
| Cash Per Share (Q) | $0.05 | |||
| Total Current Assets (Q) | 436.50K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -2.08M | |||
| Current Ratio (Q) | 0.169 | |||
| Book Value Per Share (Q) | -$0.60 | |||
| Total Assets (Q) | 495.60K | |||
| Total Current Liabilities (Q) | 2.58M | |||
| Total Debt (Q) | 377.00K | |||
| Total Liabilities (Q) | 2.58M | |||
| Total Common Equity (Q) | -2.08M | |||
| Cash Flow | ZIVO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 2.80M | |||
| Net Change in Cash (TTM) | -1.33M | |||
| Levered Free Cash Flow (TTM) | 1.03M | |||
| Cash from Operations (TTM) | -4.12M | |||
